Moderna’s CEO Stéphane Bancel spoke at the Boston College Chief Executives Club on April 5. While COVID-19 vaccine production was a big talking point for the leader of Moderna, he also touched on how mRNA technology can usher us into a longer life span, saying that he tells all of his friends to “not die” in the next ten years.
The U.S. Centers for Disease Control and Prevention (CDC) on March 29 updated its recommendation to allow certain immunocompromised individuals and people over the age of 50 to receive an additional booster dose of COVID-19 vaccines.
Moderna is broadening the company’s vaccine horizons once again using mRNA technology, widely known for its use in COVID-19 vaccinations. Moderna announced two new vaccine development programs targeting a variety of viruses.
Alnylam is suing both Moderna and Pfizer over what it claims are patent infringements related to the Cambridge, Massachusetts-based company’s biodegradable cationic lipids that it says have been foundational to the success of the mRNA-based COVID-19 vaccines developed by the two companies.
Moderna announced that the first participant was dosed in a Phase I trial of the company’s HIV trimer mRNA vaccine, mRNA-1574.
One in four children with COVID-19 symptoms develop “long COVID,” according to data pooled from 21 earlier studies conducted in Europe, Asia, Australia and South America. Also, according to a study reported on March 14 in JAMA Pediatrics, women who wish to pass protective antibodies induced by COVID-19 vaccines to their babies via breast milk should opt for the mRNA shots from Moderna or Pfizer/BioNTech.
The COVID-19 pandemic has had a significant impact on the biopharma industry. From artificial intelligence breakthroughs to at-home genetic testing, BioSpace reviews some of the ways COVID-19 has changed the industry and what we may see in the near future.
Moderna is facing additional challenges to patent the COVID-19 vaccine Spikevax, as Arbutus Biopharma and Genevant filed a lawsuit against the company challenging patent infringement.
Moderna Inc. has begun a late-stage study of a vaccine for respiratory syncytial virus (RSV) based on the same technology used to develop the company’s COVID-19 shots.
U.S. health regulators are looking at authorizing a potential fourth dose of a COVID-19 vaccine in the fall, the Wall Street Journal reported on February 19, citing sources familiar with the matter.
